CIK 0001894562 · <br>Emerging growth company
Prime Medicine, Inc.
Sign in to watch- Ticker
- PRME
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-465-0013
- Business address
- 60 FIRST ST., CAMBRIDGE, MA, 02141
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-04 | Chung Wendy Director | Grant or award · Stock Option (right to buy) | +55,000 | 55,000 | ||
| 2025-06-04 | Cahill Thomas Director | Grant or award · Stock Option (right to buy) | +55,000 | 55,000 | ||
| 2025-05-21 | LEE ANN L. Chief Technical Officer | Purchase | +100,000 | $1.13 | $113K | 100,000 |
| 2025-05-21 | Reine Allan Chief Executive Officer | Purchase | +125,000 | $1.18 | $147K | 125,000 |
| 2025-05-20 | Brudnick Richard Chief Business Officer | Purchase | +20,000 | $1.19 | $24K | 20,000 |
| 2025-05-19 | Marrazzo Jeffrey D Director | Grant or award · Stock Option (right to buy) | +800,000 | 800,000 | ||
| 2025-05-19 | Reine Allan Chief Executive Officer | Grant or award · Stock Option (right to buy) | +2,000,000 | 2,000,000 | ||
| 2025-05-08 | Reine Allan Chief Financial Officer | Grant or award · Stock Option (right to buy) | +75,000 | 850,000 | ||
| 2025-05-08 | Gottesdiener Keith Michael See Remarks | Grant or award · Stock Option (right to buy) | +100,000 | 300,000 | ||
| 2025-05-08 | LEE ANN L. Chief Technical Officer | Grant or award · Stock Option (right to buy) | +80,416 | 241,248 | ||
| 2025-02-28 | Gottesdiener Keith Michael See Remarks | Grant or award · Stock Option (right to buy) | +500,000 | 500,000 | ||
| 2025-02-27 | Alenson Carman See Remarks | Grant or award · Stock Option (right to buy) | +90,500 | 90,500 | ||
| 2025-02-27 | Goldwasser Meredith SVP, Strategy & Corporate Ops. | Grant or award · Stock Option (right to buy) | +90,500 | 90,500 | ||
| 2025-02-27 | Duffield Jeremy Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +275,000 | 275,000 | ||
| 2025-02-27 | LEE ANN L. Chief Technical Officer | Grant or award · Stock Option (right to buy) | +275,000 | 275,000 | ||
| 2025-02-27 | Brudnick Richard Chief Business Officer | Grant or award · Stock Option (right to buy) | +225,000 | 225,000 | ||
| 2025-02-27 | Reine Allan Chief Financial Officer | Grant or award · Stock Option (right to buy) | +275,000 | 275,000 | ||
| 2024-12-05 | Gottesdiener Keith Michael See Remarks | Grant or award · Stock Option (right to buy) | +100,000 | 200,000 | ||
| 2024-12-05 | Brudnick Richard Chief Business Officer | Grant or award · Stock Option (right to buy) | +19,300 | 57,900 | ||
| 2024-12-05 | Reine Allan Chief Financial Officer | Grant or award · Stock Option (right to buy) | +75,000 | 775,000 |
Page 5 of 13 · 241 trades